Fig. 2From: Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over designFlow chart. Expected number of ALL patients in the DexaDays-2 study. ALL = acute lymphoblastic leukaemia. Group 1: starting with two courses hydrocortisone, thereafter cross over to placebo. Group 2: starting with two courses placebo, thereafter cross over to hydrocortisoneBack to article page